A recent study conducted in the United Kingdom showed there is a direct relationship between controlling the amount of antihypertensive medication one person is taking and his blood pressure. The study had shown that patients who regularly checked their blood pressure at home and modified the amount of antihypertensive drugs they were taking had a more significant decrease in their blood pressure compared with patients receiving conventional care. The results of the novel study were reported in the Lancet, by Dr. Richard McManus of Primary Care Clinical Services and of the University of Birmingham. Dr. McManus said that the study, Telemonitoring and Self-Management in the Control of Hypertension (TASMINH2), was done in a primary care setting. He added that telemonitoring was also done as a “safety net.”
Ultrasound is a sound whose frequency is greater than upper limit of human hearing. The production of ultrasound is used in many different fields, and researchers are now tapping the potential of ultrasound technology in the field of stroke attacks. They have found that drugs combined with ultrasound fared better than taking medicines alone. A study on the use of ultrasound technology or sonography (an ultrasound-based diagnostic imaging technique) was presented in the New England Journal of Medicine. It looks at using ultrasound in combination with the tPA drugs during an ischemic stroke attack. The study involved 126 stroke victims. It showed that combining ultrasound technology with tPA showed an improvement in response to an ischemic stroke.
NeuroAiD originates from Traditional Chinese Medicine. It has been used in clinical practice since over 10 years. A certain number of clinical trials and case reports have been published on famous scientific journals. NeuroAiD’s safety and efficacy are being kept investigated through these persuasive records. The initial clinical trials in China on 605 patients have showed good tolerability and superiority over another TCM medicine approved for stroke, in improving neurological recovery by 2.4 times. This has given an idea to start another clinical trial at bigger scale, international and multi-centre, double-blind, placebo-controlled, and randomized Phase II Pilot study to investigate NeuroAiD’s efficacy in acute phase of stroke recovery Chimes. The study is still on-going with more than 600 randomized patients.
Over the past years, NeuroAiD™ has been prescribed by Neurologists and taken by patients, who based their decision on the good outcome for post stroke patients and the lack of adverse events (the clinical evidence). Until recently nobody knew how NeuroAiD™ acted on the brain cells and it raised many questions and even sometimes on how the benefits observed in the recovery were actually obtained. A team of world renowned French specialists in pharmacology and neurosciences have demonstrated and published recently the results of their research which establishes how NeuroAiD™ helps stroke patients recover better. This further scientific validation is a milestone for the stroke community as it will further strengthen the position of NeuroAiD™ as the treatment of choice post stroke.
In the past decade, numerous attempts focusing on neuroprotective strategies have been made to rescue neurons in the ischemic brain. Within few hours of an ischemic stroke event, acute injuries are often irreversible. The future point will be focused on how the brain tissues could be repaired. Recently, transplantation of embryonic and adult stem cells has provided new hope to stroke survivors. The essential players in this rescue mission, stem cells, are characterized by the ability to renew themselves through mitotic cell division and differentiate into a diverse range of specialized cell types. Stem cells can now be grown and transformed into specialized cells with characteristics consistent with cells of various tissues such as muscles or nerves through cell culture.